Navigation Links
Blood test may identify lung cancer patients likely to respond to erlotinib
Date:4/30/2010

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

Erlotinib is one of a class of drugs that specifically inhibits an important cell-surface molecule known as the epidermal growth factor receptor (EGFR), which is highly expressed in some forms of cancer, including lung cancer. By blocking this receptor, drugs such as erlotinib aim to slow tumor growth and proliferation.

Prof David Carbone from Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and Canadian colleagues analyzed blood samples from the NCIC Clinical Trials Group (NCIC CTG) BR.21 study that had shown that erlotinib improved survival compared to placebo in patients with advanced non-small-cell lung cancer who had already tried one or two other drugs.

In the new study, the researchers analyzed blood samples that had been taken from some patients before they started treatment in the BR.21 study. They performed this analysis on patients who received the drug and on patients who received the placebo, looking for specific proteomic profiles already known to predict outcomes in patients treated with EGFR-blockers.

"The bottom line is that the proteomic test --comparing 'good' and 'poor' profiles-- was strongly prognostic in both erlotinib and placebo arms," said Prof Carbone. "Proteomics 'good' patients also had a significantly higher response rate than proteomics 'poor' patients (9.8% vs. 0.9%, p=0.002).

Prof Carbone notes that there are other methods available to analyze the EGFR pathway of lung cancers, including sequencing of the EGFR gene, or a technique known as fluorescence in-situ hybridization (FISH) to assess EGFR gene copy number, in which tumor tissue samples are directly studied under a microscope.

"FISH overall was a better predictor of benefit, but can only be done with adequate biopsy tissue, which was available in this study only in 22% of patients. With the serum test, 99% of patients had a successful determination of proteomic status."

"Thus, I think this test may be of potential value in identifying a subgroup of patients with a good prognosis and who are likely to have response to erlotinib; it may be of particular value for those in whom tumor tissue is inadequate or unavailable," Prof Carbone said.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Blood stem-cell transplant regimen reverses sickle cell disease in adults
2. Blood Thinner Combos Risky for Heart Attack Patients
3. China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009
4. A better sign of blood vessel narrowing and early coronary artery disease
5. American Red Cross and Other U.S. Blood Centers Send Blood to Haiti
6. Analysis Examines Ultrasound Use for Blood Clots
7. Minnesota Vikings Team With Memorial Blood Centers Again for Annual Blood Drive
8. Newly discovered mechanism by which blood clots form
9. Long Before Symptoms, Blood May Reveal Rheumatoid Arthritis
10. Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says
11. Hematologists Can Now Earn CME Credits Through the Journal Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... STAT courier is ... be a convenient service for Texas, they are expanding their presence in Dallas. One ... hiring spree that will bring new jobs to the Dallas and Forth Worth market. ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Little Rock, has initiated a ... , According to the National Foundation to End Senior Hunger, Arkansas ranks first ...
(Date:12/8/2016)... ... , ... The Compretta Insurance Agency, a family owned insurance and financial consultation ... County area, is announcing the launch of a charity effort aimed at raising funds ... Pantry has worked for more than 30 years to meet the food needs of ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, ... the most comprehensive mental health systems reform legislation in more than fifty years. ... and the commitment of our elected officials to improving mental health services and ...
(Date:12/7/2016)... ... 07, 2016 , ... OC87 Recovery Diaries (oc87recoverydiaries.com) recounts the ... a unique, personal perspective through animation. , That woman is Sheri Heller, ... her private psychotherapy practice. Sheri’s mother, Pearl, lived with schizophrenia. , By ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 2016 Global Cervical Dysplasia Market: Scope ... cervical dysplasia market analyzes the current and future ... elaborate executive summary, including a market snapshot that ... The research is a combination of primary ... of our research efforts along with information collected ...
(Date:12/7/2016)... Research and Markets has announced the addition ... Global Forecast to 2021" report to their offering. ... , , The ... growing at a CAGR of 7.3% during the forecast period of 2016 ... cancer and rapidly increasing geriatric population across the globe are the primary ...
(Date:12/7/2016)... Dec. 7, 2016  Palatin Technologies, Inc. ("Palatin") ... on a previously disclosed underwritten public offering of ... acted as sole book-running manager, Roth Capital Partners ... acted as co-manager for the offering. ... in net proceeds, allowing us to continue advancing ...
Breaking Medicine Technology: